Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Xilio Therapeutics, Inc.

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.